2018
DOI: 10.1016/j.carrev.2017.08.016
|View full text |Cite
|
Sign up to set email alerts
|

Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(8 citation statements)
references
References 20 publications
0
8
0
Order By: Relevance
“…The STT-CLIPS study enrolled patients from Keck Hospital of the University of Southern California (USC) and the Los Angeles County þ USC Medical Center. 8 The study was institutional review board approved, and all participants gave written and informed consent. Inclusion criteria for patients enrolled in the study were a diagnosis of CLI (Rutherford Category IV, V, and VI) on continuous dual antiplatelet therapy with clopidogrel 75 mg daily and aspirin 81 mg daily for at least 14 days.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…The STT-CLIPS study enrolled patients from Keck Hospital of the University of Southern California (USC) and the Los Angeles County þ USC Medical Center. 8 The study was institutional review board approved, and all participants gave written and informed consent. Inclusion criteria for patients enrolled in the study were a diagnosis of CLI (Rutherford Category IV, V, and VI) on continuous dual antiplatelet therapy with clopidogrel 75 mg daily and aspirin 81 mg daily for at least 14 days.…”
Section: Methodsmentioning
confidence: 99%
“…The study found that in patients with CLTI, ticagrelor achieved greater platelet inhibition than clopidogrel during maintenance treatment and at 6 hours after daily dosing and concluded that HPR to clopidogrel in patients with CLI can be overcome by switching to ticagrelor. 8 For the current study, data from the STT-CLIPS study were retrospectively studied to assess the TW in a sample of 50 patients with CLI. The data included 4 measurements of patients' platelet reactivity using the VerifyNow P2Y12 assay: the baseline and steady state (6 hours after first daily dose) while taking clopidogrel 75 mg daily and the baseline and steady state 2 weeks after switching to ticagrelor 90 mg twice daily (Figure 1).…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Patients with high platelet reactivity while on clopidogrel showed improved platelet inhibition with the more potent P2Y12 inhibitor ticagrelor. 68…”
Section: Platelet Reactivity In Critical Limb Ischemiamentioning
confidence: 99%